Clinical trial identification: NCT03178552. Background: BFAST (NCT03178552) is a global, multi-cohort study evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations in circulating tumour DNA and activity of targeted therapies/immunotherapy in pts with 1L advanced NSCLC. In the ALK+ cohort, investigator-assessed objective response rate (ORR) was 87.4% and 12-month progression-free survival (PFS) rate was 78.4% with alectinib. We present updated ALK+ cohort biomarker analyses (median follow-up: 18.2 months)... Conclusions: Molecular heterogeneity in ALK+ NSCLC may influence clinical efficacy of ALK inhibitors such as alectinib. Larger, more mature datasets are needed to identify and validate additional biomarkers predictive of limited benefit from ALK inhibitors. READ ARTICLE
Annals of Oncology DOI:10.1016/j.annonc.2020.08.1615
Authors: S. M. Gadgeel, M. Yan, S. M. Paul, M. Mathisen, S. Mocci, Z. J. Assaf, R. Patel, E. S. Sokol, T. Mok, S. Peters, L. Paz-Ares, R. Dziadziuszko
